Global resistance of Neisseria gonorrhoeae: When theory becomes reality

Current Opinion in Infectious Diseases

Volumn 27, Issue 1, 2014, Pages 62-67

  Lewis, David A ^a,b,c  

^a NATIONAL HEALTH LABORATORY SERVICE   (South Africa)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

antimicrobial resistance; extended spectrum cephalosporin; gonorrhoea; treatment failure

Indexed keywords

AZITHROMYCIN; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; GENTAMICIN; PENICILLIN DERIVATIVE; QUINOLONE DERIVATIVE; SOLITHROMYCIN; SPECTINOMYCIN; TETRACYCLINE DERIVATIVE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ANTIMICROBIAL THERAPY; BACTERIAL CHROMOSOME; COMPLICATION; GENE MUTATION; GONORRHEA; INFECTION CONTROL; META ANALYSIS (TOPIC); MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NEISSERIA GONORRHOEAE; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); REVIEW; SINGLE DRUG DOSE;

ANTI-BACTERIAL AGENTS; BACTERIAL VACCINES; CEPHALOSPORIN RESISTANCE; CEPHALOSPORINS; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; GONORRHEA; HUMANS; NEISSERIA GONORRHOEAE;

EID: 84891825445     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0000000000000025     Document Type: Review

References (49)

1. World Health Organization. Global incidence and prevalence of selectable curable sexually transmitted infections: 2008. Geneva, Switzerland: WHO; 2012;http://apps.who.int/iris/bitstream/10665/75181/1/9789241503839-eng.pdf. [Accessed 6 October 2013]
2. Unemo M, Nicholas RA. Emergence of multidrug-resistant, extensively drugresistant and untreatable gonorrhoea. Future Microbiol 2012; 7:1401-1422.
3. Lewis DA. The Gonococcus fights back: is this time a knock out? Sex Transm Infect 2010; 86:415-421.
4. Ito M, Yasuda M, Yokoi S, et al. Remarkable increase in central Japan in 2002 of Neisseria gonorrhoeae isolates with decreased susceptibility to penicillin, tetracycline, oral cephalosporins, and fluoroquinolones. Antimicrob Agents Chemother 2004; 48:3185-3187 (Pubitemid 38989201)
5. Tanaka M, Nakayama H, Tunoe H, et al. A remarkable reduction in the susceptibility of Neisseria gonorrhoeae isolates to cephems and the selection of antibiotic regimens for the single-dose treatment of gonococcal infection in Japan. J Infect Chemother 2002; 8:81-86. (Pubitemid 34456585)
6. Deguchi T, Yasuda M, Yokoi S, et al. Treatment of uncomplicated gonococcal urethritis by double-dosing of 200 mg cefixime at a 6-h interval. J Infect Chemother 2003; 9:35-39. (Pubitemid 36504368)
7. Osaka K, Takakura T, Narukawa K, et al. Analysis of amino acid sequences of penicillin-binding protein 2 in clinical isolates of Neisseria gonorrhoeae with reduced susceptibility to cefixime and ceftriaxone. J Infect Chemother 2008; 14:195-203. (Pubitemid 351875924)
8. Ito M, Deguchi T, Mizutani KS, et al. Emergence and spread of Neisseria gonorrhoeae clinical isolates harboring mosaic-like structure of penicillinbinding protein 2 in Central Japan. Antimicrob Agents Chemother 2005; 49:137-143. (Pubitemid 40065784)
9. Ameyama S, Onodera S, Takahata M, et al. Mosaic-like structure of penicillinbinding protein 2 gene (penA) in clinical isolates of Neisseria gonorrhoeae with reduced susceptibility to cefixime. Antimicrob Agents Chemother 2002; 46:3744-3749. (Pubitemid 35403246)
10. Whiley DM, Limnios EA, Ray S, et al. Diversity of penA alterations and subtypes in Neisseria gonorrhoeae strains from Sydney, Australia, that are less susceptible to ceftriaxone. Antimicrob Agents Chemother 2007; 51:3111-3116. (Pubitemid 350067516)
11. Unemo M, Golparian D, Nicholas R, et al. High-level cefixime-and ceftriaxoneresistant Neisseria gonorrhoeae in France: novel penA mosaic allele in a successful international clone causes treatment failure. Antimicrob Agents Chemother 2012; 56:1273-1280.
12. Lewis DA, Sriruttan C, Muller EE, et al. Phenotypic and genetic characterization of the first two cases of extended-spectrum-cephalosporin- resistant Neisseria gonorrhoeae infection in South Africa and association with cefixime treatment failure. J Antimicrob Chemother 2013; 68:1267-1270.
13. Allen VG, Mitterni L, Seah C, et al. Neisseria gonorrhoeae treatment failure and susceptibility to cefixime in Toronto, Canada. JAMA 2013; 309:163-170.
14. Camara J, Serra J, Ayats J, et al. Molecular characterization of two high-level ceftriaxone-resistant Neisseria gonorrhoeae isolates detected in Catalonia, Spain. J Antimicrob Chemother 2012; 67:1858-1860.
15. Unemo M, Golparian D, Potocnik M, Jeverica S. Treatment failure of pharyngeal gonorrhoea with internationally recommended first-line ceftriaxone verified in Slovenia September 2011. Euro Surveill 2012; 17:pii:20200.
16. Lahra MM, Australian Gonococcal Surveillance Programme. Annual report of the Australian Gonococcal Surveillance Programme, 2011. Commun Dis Intell Q Rep 2012; 36:E166-E173.
17. Lo JY, Ho KM, Leung AO, et al. Ceftibuten resistance and treatment failure of Neisseria gonorrhoeae infection. Antimicrob Agents Chemother 2008; 52:3564-3567.
18. Centers for Disease Control and, Prevention. Cephalosporin susceptibility among Neisseria gonorrhoeae isolates: United States. MMWR Morb Mortal Wkly Rep 2011; 60:873-877.
19. Ison CA, Town K, Obi C, et al. Decreased susceptibility to cephalosporins among gonococci: data from the Gonococcal Resistance to Antimicrobials Surveillance Programme (GRASP) in England and Wales, 2007-2011. Lancet Infect Dis 2013; 13:762-768.
20. Huang CT, Yen MY, Wong WW, et al. Characteristics and dissemination of mosaic penicillin-binding protein 2-harboring multidrug-resistant Neisseria gonorrhoeae isolates with reduced cephalosporin susceptibility in northern Taiwan. Antimicrob Agents Chemother 2010; 54:4893-4895.
21. Tapsall JW, Ndowa F, Lewis DA, Unemo M. Meeting the public health challenge of multidrug and extensively drug-resistant Neisseria gonorrhoeae. Expert Rev Anti Infect Ther 2009; 7:821-834.
22. Ohnishi M, Golparian D, Shimuta K, et al. Is Neisseria gonorrhoeae initiating a future era of untreatable gonorrhea? Detailed characterization of the first high-level ceftriaxone resistant strain. Antimicrob Agents Chemother 2011; 55:3538-3545.
23. Shimuta K, Unemo M, Nakayama SI, et al. Antimicrobial resistance and molecular typing of Neisseria gonorrhoeae isolates in Kyoto and Osaka, Japan in 2010-2012: intensified surveillance after identification of the first high-level ceftriaxone resistant strain H041. Antimicrob Agents Chemother 2013; 57:5225-5232.
24. Chisholm SA, Alexander S, Desouza-Thomas L, et al. Emergence of a Neisseria gonorrhoeae clone showing decreased susceptibility to cefixime in England and Wales. J Antimicrob Chemother 2011; 66:2509-2512.
25. Golparian D, Hellmark B, Fredlund H, Unemo M. Emergence, spread and characteristics of Neisseria gonorrhoeae isolates with in vitro decreased susceptibility and resistance to extended-spectrum cephalosporins in Sweden. Sex Transm Infect 2010; 86:454-460.
26. Chisholm SA, Unemo M, Quaye N, et al. Molecular epidemiological typing within the European Gonococcal Antimicrobial Resistance Surveillance Programme reveals predominance of a multidrug-resistant clone. Euro Surveill 2013; 18:pii:20358.
27. Pandori M, Barry PM, Wu A, et al. Mosaic penicillin-binding protein 2 in Neisseria gonorrhoeae isolates collected in 2008 in San Francisco, California. Antimicrob Agents Chemother 2009; 53:4032-4034.
28. Tapsall J, Read P, Carmody C, et al. Two cases of failed ceftriaxone treatment in pharyngeal gonorrhoea verified by molecular microbiological methods. J Med Microbiol 2009; 58:683-687.
29. UnemoM, Golparian D, Hestner A. Ceftriaxone treatment failure of pharyngeal gonorrhoea verified by international recommendations, Sweden, July 2010. Euro Surveill 2011; 16:pii:19792.
30. Boslego JW, Tramont EC, Takafuji ET, et al. Effect of spectinomycin use on the prevalence of spectinomycin-resistant and of penicillinase-producing Neisseria gonorrhoeae. N Engl J Med 1987; 317:272-278. (Pubitemid 17100106)
31. Unemo M, Golparian D, Skogen V, et al. Neisseria gonorrhoeae strain with high-level resistance to spectinomycin due to a novel resistance mechanism (mutated ribosomal protein S5) verified in Norway. Antimicrob Agents Chemother 2013; 57:1057-1061.
32. Brown LB, Krysiak R, Kamanga G, et al. Neisseria gonorrhoeae antimicrobial susceptibility in Lilongwe, Malawi, 2007. Sex Transm Dis 2010; 37:169-172.
33. Ross JD, Lewis DA. Cephalosporin resistant Neisseria gonorrhoeae: time to consider gentamicin? Sex Transm Infect 2012; 88:6-8.
34. Chisholm SA, Quaye N, Cole MJ, et al. An evaluation of gentamicin susceptibility of Neisseria gonorrhoeae isolates in Europe. J Antimicrob Chemother 2011; 66:592-595.
35. Dowell D, Kirkcaldy RD. Effectiveness of gentamicin for gonorrhoea treatment: systematic review and meta-analysis. Postgrad Med J 2013; 89:142-147.
36. Bignell C, Garley J. Azithromycin in the treatment of infection with Neisseria gonorrhoeae. Sex Transm Infect 2010; 86:422-426.
37. Ison C, Hussey J, Sankar K, et al. Gonorrhoea treatment failures to cefixime and azithromycin in England, 2010. Euro Surveill 2011; 16:pii:19833.
38. Young H, Moyes A, McMillan A. Azithromycin and erythromycin resistant Neisseria gonorrhoeae following treatment with azithromycin. Int J STD AIDS 1997; 8:299-302. (Pubitemid 27202413)
39. Centers for Disease Control and Prevention. Update to CDC's Sexually transmitted diseases treatment guidelines, 2010: oral cephalosporins no longer a recommended treatment for gonococcal infections. MMWR Morb Mortal Wkly Rep 2012; 61:590-594.
40. Bignell C, Fitzgerald M. UK national guideline for the management of gonorrhoea in adults, 2011. Int J STD AIDS 2011; 22:541-547.
41. Kirkcaldy RD. Treatment of gonorrhoea in an era of emerging cephalosporin resistance and results of a randomised trial of new potential treatment options [abstract]. Sex Transm Infect 2013; 89 (Suppl 1):A14-A15.
42. Unemo M, Golparian D, Limnios A, et al. In vitro activity of ertapenem versus ceftriaxone against Neisseria gonorrhoeae isolates with highly diverse ceftriaxone MIC values and effects of ceftriaxone resistance determinants: ertapenem for treatment of gonorrhea? Antimicrob Agents Chemother 2012; 56:3603-3609.
43. Golparian D, Fernandes P, Ohnishi M, et al. In vitro activity of the new fluoroketolide solithromycin (CEM-101) against a large collection of clinical Neisseria gonorrhoeae isolates and international reference strains, including those with high-level antimicrobial resistance: potential treatment option for gonorrhea? Antimicrob Agents Chemother 2012; 56:2739-2742.
44. Llano-Sotelo B, Dunkle J, Klepacki D, et al. Binding and action of CEM-101, a new fluoroketolide antibiotic that inhibits protein synthesis. Antimicrob Agents Chemother 2010; 54:4961-4970.
45. Simonsen GS, Tapsall JW, Allegranzi B, et al. The antimicrobial resistance containment and surveillance approach: a public health tool. Bull World Health Organ 2004; 82:928-934. (Pubitemid 40065161)
46. World Health Organization. Global action plan to control the spread and impact of antimicrobial resistance in Neisseria gonorrhoeae. Geneva, Switzerland: WHO; 2012; http://whqlibdoc.who.int/publications/2012/ 9789241503501-eng.pdf. [Accessed 6 October 2013]
47. Centers for Disease Control and Prevention. Cephalosporin-resistant Neisseria gonorrhoeae public health response plan. Atlanta, Georgia, USA: Centers for Disease Control and Prevention; 2012; http://www.cdc.gov/std/ treatment/ceph-r-responseplanjuly30-2012.pdf. [Accessed 6 October 2013]
48. Health Protection Agency. Gonoccocal Resistance to Antimicrobials Surveillance Programme (GRASP) Action Plan for England and Wales: Informing the Public Health Response. London, Switzerland: Health Protection Agency (HPA); 2013; http://www.hpa.org.uk/webc/HPAwebFile/HPA web-C/1317138215954. [Accessed 6 October 2013]
49. European Centre for Disease Control and Prevention. Response plan to control and manage the threat of multidrug-resistant gonorrhoea in Europe Stockholm: ECDC; 2012; http://www.ecdc.europa.eu/en/publications/publi cations/1206-ecdc-mdr-gonorrhoea-response-plan.pdf. [Accessed 6 October 2013]